A Computer Sciences Corp. (NYSE: CSC) company has won a 10-year, $90 million follow-on contract to examine infectious disease therapeutics for the National Institutes of Health’s anti-infectives program.
DynPort Vaccine Company LLC will conduct first phase clinical trials of new compounds to support the National Institute of Allergy and Infectious Diseases’ therapeutic products study, CSC said Tuesday.
DVC will also determine the pharmacokinetic and pharmacodynamic properties of the compounds for human dosing purposes in collaboration with Quintiles, Health Decisions and WCCT Global.
Gary Nabors, president of DVC, said the team will continue to work with NIAID to evaluate new compounds in an effort “to meet the growing need for new anti-infectives.”
Under the indefinite-delivery/indefinite-quantity contract, DVC will manage the program and clinical operations, quality assurance, and development of protocols and concepts.
Quintiles, Health Decisions and WCCT Global will perform clinical research and provide services to implement approved clinical trial protocols.